Cerus Corporation  

(Public, NASDAQ:CERS)   Watch this stock  
Find more results for CERS
4.30
+0.25 (6.17%)
After Hours: 4.33 +0.03 (0.70%)
Oct 20, 7:58PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.14 - 4.31
52 week 3.48 - 8.00
Open 4.23
Vol / Avg. 1.65M/1.14M
Mkt cap 299.89M
P/E     -
Div/yield     -
EPS -0.48
Shares 74.05M
Beta 2.01
Inst. own 61%
Sep 10, 2014
Cerus Corp at Morgan Stanley Healthcare Conference
Sep 3, 2014
Cerus Corp at Robert W. Baird & Co. Inc Health Care Conference
Aug 12, 2014
Cerus Corp at Wedbush Securities Life Sciences Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -88.23% -109.28%
Operating margin -127.94% -71.36%
EBITD margin - -69.95%
Return on average assets -40.56% -65.51%
Return on average equity -68.35% -140.02%
Employees 115 -
CDP Score - -

Address

2550 Stanwell Drive
CONCORD, CA 94520
United States - Map
+1-925-2886000 (Phone)
+1-925-2886001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on the Company's technology for controlling biological replication, is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The Company has worldwide rights for its intercepts Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received Conformite Europeene (CE) marks and are being marketed and sold in a number of countries in Europe, The Commonwealth of Independent States, the Middle East and selected countries in other regions worldwide. The Company sells both the platelet and plasma systems using its direct sales force and through distributors.

Officers and directors

Daniel N. Swisher Jr. Independent Chairman of the Board
Age: 51
Bio & Compensation  - Reuters
William M. Greenman President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Kevin D. Green Chief Financial Officer, Vice President - Finance
Age: 42
Bio & Compensation  - Reuters
Caspar Hogeboom President, Cerus Europe
Age: 55
Bio & Compensation  - Reuters
Laurence M. Corash M.D. Senior Vice President, Chief Medical and Chief Scientific Officer, Director
Age: 70
Bio & Compensation  - Reuters
Carol M. Moore Senior Vice President - Regulatory Affairs, Quality and Clinical
Age: 64
Bio & Compensation  - Reuters
Chrystal N. Menard Chief Legal Officer
Age: 43
Bio & Compensation  - Reuters
Timothy Bruce Anderson Independent Director
Age: 67
Bio & Compensation  - Reuters
Bruce C. Cozadd Independent Director
Age: 50
Bio & Compensation  - Reuters
Gail Gaumer Schulze Independent Director
Age: 62
Bio & Compensation  - Reuters